医学临床研究
  2025年6月12日 星期四           首 页    |    期刊简介    |    编委会    |    投稿指南    |    期刊订阅    |    广告合作    |    留言板    |    联系我们    |    English
医学临床研究  2021, Vol. 38 Issue (9): 1334-1337    DOI: 10.3969/j.issn.1671-7171.2021.09.016
  论著 本期目录 | 过刊浏览 | 高级检索 |
和法论治乳腺癌内分泌治疗后类更年期综合征的疗效观察
武晓妹1a, 罗何婷2, 刘米花1a, 王利群1b*
1.咸阳彩虹医院:a.内三科;b.中医内科,陕西 咸阳 712021;
2.咸阳市中心医院保健科,陕西 咸阳 712000
Study on Chinese Medicine Way of Hefa (Harmonic Herbs) in the Treatment of Menopausal Syndrome after Endocrine Therapy of Breast Cancer
WU Xiao-mei, LUO He-ting, LIU Mi-hua, et al
Department of Internal Medicine, Xianyang Rainbow Hospital, Xianyang Shaanxi 712000
全文: PDF (1143 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 【目的】探讨和法论治乳腺癌内分泌治疗后类更年期综合征的临床疗效。【方法】选取2017年1月至2020年1月咸阳彩虹医院诊治的78例乳腺癌内分泌治疗后类更年期综合征患者纳入研究对象,按照随机数表法分为观察组和对照组,每组39例。对照组使用内分泌药物治疗的同时加用谷维素片与维生素B1,观察组在对照组基础上行和法论治,两组患者均持续用药3个月。比较两组患者临床疗效及治疗前后中医证候评分、血清性激素[雌二醇(E2)、黄体生成素(LH)、卵泡刺激素(FSH)]、肿瘤标志物[糖类抗原15-3(CA15-3)、糖类抗原125(CA125)]水平 。【结果】观察组患者总有效率为92.31%(36/39),显著高于对照组的74.36%(29/39),其差异有统计学意义(χ2=4.523,P=0.033)。两组患者治疗前中医证候评分比较差异无统计学意义(P>0.05);治疗后,观察组患者中医证候月经紊乱、潮热汗出、情绪改变、头晕耳鸣、腰膝酸软、心悸失眠评分显著低于治疗前及对照组治疗后,其差异均有统计学意义(P<0.05)。两组患者治疗前后E2、LH、FSH、CA15-3、CA125水平比较差异无统计学意义(P>0.05)。【结论】和法论治用于乳腺癌内分泌治疗后类更年期综合征可明显缓解患者的临床症状,且对性激素及肿瘤标志物相关指标无明显影响。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
武晓妹
罗何婷
刘米花
王利群
关键词 乳腺肿瘤/心理学托瑞米芬/治疗应用芳香酶抑制剂/治疗应用更年期综合征    
Abstract:【Objective】To explore the clinical effects of treating postmenopausal syndrome after endocrine therapy of breast cancer with Chinese medicine way of Hefa (harmonic herbs). 【Methods】A total of 78 patients with menopausal syndrome after endocrine therapy of breast cancer from January 2018 to January 2020 in our hospital were selected for the study. All patients were divided into the observation group and the control group by random number table method, with 39 cases respectively. The control group was treated with endocrine drugs, oryzanol tablets and vitamin B1 at the same time. The observation group was treated with traditional Chinese medicine way of Hefa (harmonic herbs) on the basis of the control group. The clinical efficacy, TCM syndrome score, serum sex hormones [estradiol (E2), luteinizing hormone (LH), follicle stimulating hormone (FSH)], tumor markers [carbohydrate antigen 15-3 (CA15-3), carbohydrate antigen 125 (CA125)] were compared between the two groups before and after treatment. 【Results】The total effective rate of the observation group was 92.31%, which was significantly higher than 74.36% of the control group (P<0.05).There was no significant difference in TCM syndrome score between the two groups before treatment (P>0.05). After treatment, the scores of menstrual disorder, hot flashes and sweating, emotional changes, dizziness and tinnitus, waist and knee soreness, palpitation and insomnia in the observation group were significantly lower than those before treatment and after treatment in the control group, and the difference was statistically significant (P<0.05).There were no significant differences in the levels of E2, LH, FSH, CA15-3 and CA125 between and within the two groups before and after treatment (P>0.05). 【Conclusion】After endocrine therapy of breast cancer, patients with menopausal like syndrome can be treated with traditional Chinese medicine way of Hefa (harmony) to significantly relieve the clinical symptoms of patients without significant impact on sex hormones and tumor markers.
Key wordsBreast Neoplasms/PX    Toremifene /TU    Aromatase Inhibitors/TU    CLIMACTERIC SYNDROME
收稿日期: 2021-04-08     
中图分类号:  R737.9  
通讯作者: *E-mail:463349985@qq.com   
引用本文:   
武晓妹, 罗何婷, 刘米花, 王利群. 和法论治乳腺癌内分泌治疗后类更年期综合征的疗效观察[J]. 医学临床研究, 2021, 38(9): 1334-1337.
WU Xiao-mei, LUO He-ting, LIU Mi-hua, et al. Study on Chinese Medicine Way of Hefa (Harmonic Herbs) in the Treatment of Menopausal Syndrome after Endocrine Therapy of Breast Cancer. JOURNAL OF CLINICAL RESEARCH, 2021, 38(9): 1334-1337.
链接本文:  
http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2021.09.016     或     http://journal07.magtech.org.cn/yxlcyj/CN/Y2021/V38/I9/1334
版权所有 © 2013 医学临床研究杂志社  湘ICP备13012052号-1
办公地址:湖南省长沙市芙蓉区新军路43号煤炭大院主办公楼6楼621、623、632、636室 邮编:410011 电话(传真):0731-84824007 E-mail:jcr_cs.hn@vip.163.com
技术支持:北京玛格泰克科技发展有限公司 技术支持:support@magtech.com.cn